Introduction
Rare ovarian tumors—including borderline ovarian tumors (BOTs), germ cell tumors, and sex cord-stromal tumors—frequently affect women of reproductive age. The management of these patients presents a complex clinical intersection between oncology, endocrinology, and reproductive medicine. While life-saving treatments like surgery and chemotherapy are paramount, they often induce premature menopause or infertility, significantly impacting long-term quality of life. Clinicians face a persistent dilemma: how to manage hormonal needs (contraception, HRT) and fertility preservation without increasing the risk of tumor recurrence, particularly in hormone-sensitive subtypes.
Methodology: The Delphi Consensus
Given the rarity of these conditions, large-scale randomized controlled trials—the gold standard of clinical evidence—are largely absent. To address this gap, the TMRG/GINECO national network convened a panel of 35 French experts across oncology, surgery, gynecology, reproductive medicine, and pathology.
The panel utilized the Delphi method, a structured communication technique designed to reach a formal consensus when literature is scarce. Following a systematic review of available case series and retrospective cohorts, the experts engaged in two rounds of anonymous rating. A "strong agreement" was reached for 35 specific recommendations, defined by high median scores and a lack of extreme outliers in the voting distribution.
Risk Stratification by Hormone Sensitivity
The cornerstone of these guidelines is the categorization of risk based on the biological hormone-sensitivity of the specific tumor type. This framework allows clinicians to move away from a "one-size-fits-all" approach.
1. Hormone-Insensitive (The "Safe" Zone)
Germ Cell Tumors are generally considered hormone-insensitive. For survivors of these tumors, the panel concluded that hormone replacement therapy (HRT), hormonal contraception, and controlled ovarian stimulation (COS) for fertility preservation are safe and should not be restricted.
2. Variable Sensitivity (The "Caution" Zone)
Borderline Ovarian Tumors (BOTs) represent a middle ground. While most BOTs allow for standard hormonal management, the presence of "high-risk" features—such as invasive peritoneal implants or micropapillary patterns—necessitates a cautious, case-by-case multidisciplinary approach.
3. Hormone-Sensitive (The "Danger" Zone)
Sex Cord-Stromal Tumors (e.g., adult granulosa cell tumors) and Low-Grade Epithelial Subtypes (e.g., low-grade serous adenocarcinomas) are highly hormone-sensitive. In these cases, estrogen-containing treatments are generally contraindicated. Exceptions may only be discussed for very early-stage disease (Stage IA/IB) within a multidisciplinary setting.
Key Clinical Recommendations
The consensus yielded 35 formal recommendations, focusing on three primary areas:
- Fertility Preservation: Ovarian stimulation followed by oocyte or embryo vitrification is the preferred strategy. However, it is contraindicated in most hormone-sensitive rare epithelial and sex cord tumors due to the potential risks associated with high gonadotropin or estrogen levels.
- Contraception: Combined estroprogestin options should be avoided during active cancer treatment to mitigate thromboembolic risks. For long-term use in hormone-sensitive survivors, progestin-only options are recommended as a safer alternative.
- Hormone Replacement Therapy (HRT): HRT is strongly recommended for survivors of germ cell tumors and most BOTs to prevent the long-term morbidities of premature menopause, such as cardiovascular disease and osteoporosis. Conversely, HRT is generally avoided in low-grade serous or endometrioid cancers unless the disease was caught at an extremely early stage.
Limitations and Future Directions
The authors acknowledge that these recommendations are primarily based on expert opinion and limited retrospective data. The inherent uncertainty of expert consensus highlights the need for more robust evidence. Future efforts should prioritize the development of international registries to pool data on these rare cohorts, specifically focusing on the long-term safety of HRT and pregnancy outcomes following assisted reproductive technology.
Summary updated